A court has ruled in favor of Indian generic drug maker Ranbaxy Labs in a case concerning a generic blood pressure drug, the legal firm representing the drug maker said.
Par Pharmaceutical Cos. has contracted with AstraZeneca to distribute an authorized generic version of a drug used to treat high blood pressure, Par said.
A Takeda drug designed to treat hypertension was statistically superior to another drug combination in reducing systolic blood pressure among patients in a 10-week, late-stage clinical trial.
A class of drugs commonly used to control blood pressure does not increase patients’ risk of developing cancer, according to the Food and Drug Administration.